Results 241 to 250 of about 44,629 (299)

Efficacy of Hepatic Artery Infusion Chemotherapy Combined With Regorafenib and Sintilimab Versus Regorafenib Alone in MSS/pMMR Colorectal Cancer Liver Metastases After Second‐Line Treatment Failure

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer liver metastases (CRCLM) have limited treatment options after failure of second‐line systemic therapies. Hepatic artery infusion chemotherapy (HAIC) combined with targeted therapy and immunotherapy may offer improved outcomes.
Ran You, Qingyu Xu, Lixing Wang, Bin Leng, Chendong Wang, Zeyu Yu, Ya Lu, Lingfeng Diao, Yi Lu, Guowen Yin   +9 more
wiley   +1 more source

Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD‐1 Inhibitors in Advanced Hepatocellular Carcinoma

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Aims This study aimed to explore the predictive value of intratumoral proton density fat fraction (PDFF) and the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐programmed cell death protein 1 (anti‐PD‐1) therapy in advanced hepatocellular carcinoma (HCC).
Yujie Ye, Yunzheng Li, Yanjun Lu, Yanchao Xu, Laizhu Zhang, Yican Zhu, Huan Li, Binghua Li, Min Zhou, Decai Yu   +9 more
wiley   +1 more source

Prolonged Diagnostic Latency and Long-term Surveillance in Anti-Ri Antibody-positive Opsoclonus-myoclonus Syndrome with Carcinoma of Unknown Primary. [PDF]

Intern Med
Ibukuro M, Kida H, Sarukawa H, Komatsu T, Sakai K, Iguchi Y.   +5 more
europepmc   +1 more source

The emerging role of dendritic cells in the tumor microenvironment: from antigen presentation to targeted immunotherapy. [PDF]

Cell Death Dis
Xie Z, Fang Y, Zhang X, Fang Y, Li R, Guo Y, Yang Y, Yang S, Song L.   +8 more
europepmc   +1 more source

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

Advances in Breast Cancer Research: Immunological, Pathological, and Pharmacological Perspectives for Improving Patient Outcomes. [PDF]

Int J Mol Sci
Crocamo S, Dos Santos EC, Abdelhay E.
europepmc   +1 more source

Parvimonas micra promotes carcinogenesis of colorectal cancer through phenyllactic acid‐induced DNA damage

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Multiomics analysis of the faecal samples from CRC patients found that upregulation of P. micra and PLA was associated with the CRC development. PLA from P. micra via pdhD genes could induce DNA damage via AHR signalling pathway to mediate carcinogenesis.
Shuang Guo, Mujia Cao, Jinjie Wu, Wenhao Ma, Dayi Liang, Hongyu Xie, Yanchun Xie, Zhanhao Luo, Peng Lai, Danling Liu, Wanyi Zeng, Jingbiao Zheng, Mengze Xing, Xiqi Yin, Min Xia, Zhen He   +15 more
wiley   +1 more source

A ribonucleotide carbohydrate system (iRNC) enhances antigen presentation and controls glioblastoma. [PDF]

Theranostics
Kim HS, Oh J, Jeon J, Fei F, Parvanian S, Kohler R, Garris C, Weissleder R.   +7 more
europepmc   +1 more source

The Critical Role of GALNTs-Regulated O-GalNAc Glycosylation in Cancer Malignancy. [PDF]

FASEB J
Liu J, Wu S, Zhang G, Li J, Yin Y, Uiiah A, Peng S, Fu Y.   +7 more
europepmc   +1 more source

The Role of MUC1 in Gastric Cancer Development. [PDF]

Cancers (Basel)
Radziejewska I.
europepmc   +1 more source